107 related articles for article (PubMed ID: 15659510)
1. Benign lesions in cancer patients: Case 1. Sarcoidosis after chemoradiation for head and neck cancer.
Yao M; Funk GF; Goldstein DP; DeYoung BR; Graham MM
J Clin Oncol; 2005 Jan; 23(3):640-1. PubMed ID: 15659510
[No Abstract] [Full Text] [Related]
2. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
3. Decreased hearing after combined modality therapy for head and neck cancer.
Pearson SE; Meyer AC; Adams GL; Ondrey FG
Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of low-dose cisplatin-based chemo-irradiation in assessing hearing loss for locally advanced head and neck cancer.
Liao XB; Yan SX
Radiother Oncol; 2009 Feb; 90(2):282, author reply 282-3. PubMed ID: 19042049
[No Abstract] [Full Text] [Related]
5. Chemoradiation for advanced head and neck cancer: potential for improving results to match those of current treatment modalities for early-stage tumors--long-term results of hyperfractionated chemoradiation with carbogen breathing and anemia correction with erythropoietin.
Villar A; Martinez JC; de Serdio JL
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1382-8. PubMed ID: 18037586
[TBL] [Abstract][Full Text] [Related]
6. FDG uptake after intraarterial chemotherapy in head and neck cancer.
Döbert N; Kovács AF; Menzel C; Engels K; Kranert WT; Grünwald F
Nuklearmedizin; 2006; 45(6):243-7. PubMed ID: 17149492
[TBL] [Abstract][Full Text] [Related]
7. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy.
Tan A; Adelstein DJ; Rybicki LA; Saxton JP; Esclamado RM; Wood BG; Lorenz RR; Strome M; Carroll MA
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):435-40. PubMed ID: 17515501
[TBL] [Abstract][Full Text] [Related]
8. Influence of low-dose daily cisplatin on the distant metastasis-free survival of patients with locally advanced nonmetastatic head and neck cancer treated with radiation therapy.
Jeremić B; Milicić B
Radiother Oncol; 2008 May; 87(2):201-3. PubMed ID: 18207598
[TBL] [Abstract][Full Text] [Related]
9. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck.
Zimmer LA; Branstetter BF; Nayak JV; Johnson JT
Laryngoscope; 2005 Nov; 115(11):2029-34. PubMed ID: 16319618
[TBL] [Abstract][Full Text] [Related]
10. Concomitant boost radiotherapy with concurrent weekly cisplatin in advanced head and neck cancers: a phase II trial.
Kumar S; Pandey M; Lal P; Rastogi N; Maria Das KJ; Dimri K
Radiother Oncol; 2005 May; 75(2):186-92. PubMed ID: 16086908
[TBL] [Abstract][Full Text] [Related]
11. Sarcoidosis.
Bergot E; Paparel P; Zalcman G
N Engl J Med; 2008 Mar; 358(13):1404; author reply 1404-5. PubMed ID: 18376441
[No Abstract] [Full Text] [Related]
12. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
13. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
14. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
[TBL] [Abstract][Full Text] [Related]
15. Concomitant boost radiotherapy with concurrent weekly cisplatin in advanced head and neck cancers: a phase II trial.
Munshi A; Pandey KC; Susheela SP
Radiother Oncol; 2006 Jan; 78(1):109-10; author reply 108-9. PubMed ID: 16307815
[No Abstract] [Full Text] [Related]
16. Positron emission tomography/computed tomography for staging and restaging of head and neck cancer: comparison with positron emission tomography read together with contrast-enhanced computed tomography.
Goerres GW; Schuknecht B; Schmid DT; Stoeckli SJ; Hany TF
Clin Imaging; 2008; 32(6):431-7. PubMed ID: 19006770
[TBL] [Abstract][Full Text] [Related]
17. Whole-body 18FDG PET-CT imaging of systemic sarcoidosis: ophthalmic oncology and uveitis.
Shulman JP; Latkany P; Chin KJ; Finger PT
Ocul Immunol Inflamm; 2009; 17(2):95-100. PubMed ID: 19412870
[TBL] [Abstract][Full Text] [Related]
18. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18.
Basu D; Siegel BA; McDonald DJ; Nussenbaum B
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):801-5. PubMed ID: 17709620
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin as a radiosensitizer in the treatment of locally advanced head and neck cancer.
Altundag O; Altundag K; Morandi P; Hanrahan E
Oral Oncol; 2005 Apr; 41(4):435. PubMed ID: 15792617
[No Abstract] [Full Text] [Related]
20. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
